| 1. Wang Y, Liu S, Hao H, Yang C, Tu T, Fan Y, Song Z, Yang K, Zhang H*, Li H*, Ma Y*.Laboratory Parameters as Diagnostic Indicators in Venous Hypertensive Myelopathy. .2024.online. .SCI(含SCIE) |
| 2. Li HF*, Lu ZN.Possible benefit of second intravenous immunoglobulin course in Guillain-Barré syndrome patients with potentially poor prognosis. .2024.31(4):. .SCI(含SCIE) |
| 3. Li HF*, Gao F, Chen XJ..Autoantibody levels as biomarkers of disease activity in the management of myasthenia gravis. .2023.30(4). .SCI(含SCIE) |
| 4. Li HF*, Gilhus NE*, Xue Q, Gao F.Phenotypes of myasthenia gravis, volume II.. .2023.14. .SCI(含SCIE) |
| 5. Lu H, Ma YJ, Liu H, Li HF.*.A 49-Year-Old Woman With Isolated Sinus Intracranial Dural Arteriovenous Fistula With Perimedullary Drainage. .2023.100(19. .SCI(含SCIE) |
| 6. Li HF*.Optimal validation of accuracy in antibody assays and reasonable definition of antibody positive/negative subgroups in neuroimmune diseases: a narrative review.. .2023.11(7). .EI |
| 7. Zhang X, Hao H, Jin T, Qiu W, Yang H, Xue Q, Yin J, Shi Z, Yu H, Ji X, Sun X, Zeng Q, Liu X, Wang J, Li H, He X, Yang J, Li Y, Liu S, Lau AY, Gao F, Hu S, Chu S, Ding D, Zhou H,* Li H*, Chen X*..Cerebrospinal fluid oligoclonal bands in Chinese patients with multiple sclerosis: the prevalence and its association with clinical features. .2023.14. .SCI(含SCIE) |
| 8. Li HF*, Hu SM, Yin J, Yang H.Score fluctuation might be associated with a higher placebo rate in the RAISE trial.. .2023.22(11). .SCI(含SCIE) |
| 9. Li HF*, Hu SM, Lv M.Association of Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome. .2022.327(4). .SCI(含SCIE) |
| 10. Jiang P, Li J, Li HY, Zhang B, Yue YX, Wang YS, Zi XC, Liu SS, Li YF, Jiao LD, Li HF*.Minimal Manifestation Status Indicates a Stable State in Myasthenia Gravis: A Quantitative Study. .2022.13. .SCI(含SCIE) |
| 11. Shao K, Yue YX, Zhao LM, Hao HJ, Ding XJ, Jiang P, Yan CZ, Li HF*.Optimization of the cut-offs in acetylcholine receptor antibodies and diagnostic performance in myasthenia gravis patients. .2022.533. .SCI(含SCIE) |
| 12. Li HF, Gilhus NE, Yang H, Chen X.Phenotypes of myasthenia gravis.. .2022.13. .SCI(含SCIE) |
| 13. Yan Li HY, Jiang P, Xie Y, Liang B, Li L, Zhao CP, Yue YX, Li HF*.Criteria for Treatment Response in Myasthenia Gravis: Comparison Between Absolute Change and Improvement Percentage in Severity Scores. .2022.13. .SCI(含SCIE) |
| 14. Li HY, Shao LY, Song M, Hu SM, Yue YX, Li HF*.Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study.. .2022.13. . |
| 15. 李海峰.重症肌无力治疗策略的演变及个体化治疗路径. .2021.101(31). . |
| 16. Hu SM, Fang XH, Li HF*.Postoperative Atrial Fibrillation After Noncardiac Surgery and Stroke.. .2021.325(2). .SCI(含SCIE) |
| 17. Han JL, Yue YX, Gao X, Xie YC, Hao HJ, Li HY, Yu XL, Li J, Duan RS*, Li HF*.Vitamin D Receptor Polymorphism and Myasthenia Gravis in Chinese Han Population.. .2021.12. .SSCI |
| 18. Yue YX, Gao X, Tang TP, Xie Y, Gu CK, Hao HJ, Li HY, Ding XJ, Song M, Guo SG*, Li HF*..Complement C3 polymorphism is associated with the susceptibility of myasthenia gravis in Chinese adult patients.. .2021.353. .SCI(含SCIE) |
| 19. Li HF*, Hao HJ, Chen XJ.Provisional case definitions for COVID-19-associated neurological disease.. .2020.19(11). .SCI(含SCIE) |
| 20. Li HF*, Liang B, Li HY.Risk stratification for stroke in atrial fibrillation: incorporating neurologists in the comprehensive management.. .2019.40(36). .SCI(含SCIE) |
